Norman E. “Ned” Sharpless, MD, who became director of the National Cancer Institute in October 2017, recently unveiled areas of opportunity that he believes are particularly important for accelerating cancer research.Read More
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah) to include certain patients with non-Hodgkin lymphoma.
In August 2017, tisagenlecleucel became …
The AACR Annual Meeting 2018 drew more than 22,600 people to Chicago, providing a front-row seat to some exciting developments in cancer research. Whether it was the practice-changing results of …Read More
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form …Read More
This post originally appeared on the Cancer Today website.
Roads and roadblocks, both literal and metaphorical, figured into a panel discussion on the state of cancer research and care in the …
An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments work by stimulating the patient’s immune system to effectively target and …Read More
Monday ushered in a ray of hope and promise for the lung cancer community at the AACR Annual Meeting 2018 – the clinical trial plenary session featured blockbuster trials testing …Read More
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include the treatment of certain patients with the most common form of lung cancer—non–small cell lung cancer (NSCLC).Read More
Last week, the U.S. Food and Drug Administration (FDA) approved the antihormone agent apalutamide (Erleada) for treating men with nonmetastatic prostate cancer that has stopped responding to standard antihormone treatments.Read More
The field of medical oncology is undergoing a remarkable transformation. Cancers that were once considered death sentences, such as multiple myeloma and metastatic melanoma, are turning into chronic diseases due to the use of novel, targeted systemic therapies. Immunotherapy is altering the natural history of certain malignancies.Read More